The cytochrome P450 2D6 (CYP2D6) is a liver enzyme involved in the metabolism of more than 25% of the most frequently used drugs in the clinical field. Variants of the highly polymorphic CYP2D6 gene are associated with altered enzymatic function, ranging from a complete lack of activity to an ultrarapid metabolization of drugs.
This altered CYP2D6 activity causes an inter- individual variability in drug-response. Patients with a defective or over-active CYP2D6 enzyme are either at risk to develop severe adverse events or do not reach the therapeutic window for effective treatment with a specific drug. Hence, pharmacogenetic guidelines recommend a CYP2D6-related dose-adjustment for numerous drugs.
The ViennaLab PGX-CYP2D6 XL StripAssay® in combination with the CYP2D6 RealFast CNV Assay identifies patients with an altered CYP2D6 enzyme function. Comprehensive CYP2D6 genotyping optimizes the choice of medication and/or the adjustment of drug dosage and consequently reduces the risk of adverse events or lowered treatment efficacy.
After completion, Goffin Molecular Technologies will contact you as soon as possible.
You must be logged in to post a comment.